Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.

By S. Leucht, Andrea Cipriani, L. Spineli, Dimitris Mavridis, Deniz Örey, F. Richter, M. Samara, C. Barbui, R. Engel, John R. Geddes and 5 more. The Lancet, 2013

2,295 citations recorded by the source corpus.

Subfields: Molecular Biology, Pharmacology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/2b2b20add6e4b1be0da392c7f556c2d8e40db2a0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Pharmacology

In Psychiatry and Mental health

Citations in the corpus

Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder (2015, background): “QTc prolongation with lurasidone and aripiprazole is judged to be clinically insignificant (32,133).”
Evidence-based guidelines for treating bipolar disorder: revised third edition Recommendations from the British Association for Psychopharmacology (2009, positive): “Lurasidone appears to have a more favourable metabolic profile than either quetiapine or olanzapine (Leucht et al., 2013).”
Dose-Specific Adverse Drug Reaction Identification in Electronic Patient Records: Temporal Data Mining in an Inpatient Psychiatric Population (2014, result): “…haloperidol and aripiprazole show a lower proportion of sedated patients in our study, as well as less sedation compared with placebo in the study by Leucht et al. [37] The sedative proﬁle of chlorprothixene seen in the investigation might be the real indication for many prescriptions of this drug.”
Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis (2020, background): “on acute treatment, which we define as 6-weeks duration.(4) If 6-week data are not”
The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. (2019, positive): “244 Although sedation might have short-term benefits for an acutely exacerbated or agitated patient, in the long term, somnolence and sedation can affect physical activity, The Lancet Psychiatry Commission bodyweight, concentration, and the ability to participate in daily activities or psychosocial…”